tradingkey.logo

tradingkey.logo
āļ„āđ‰āļ™āļŦāļē


ImageneBio Ord Shs

IMA
āđ€āļžāļīāđˆāļĄāļĨāļ‡āđƒāļ™āļĢāļēāļĒāļāļēāļĢāļ•āļīāļ”āļ•āļēāļĄ
3.470USD
+0.020+0.58%
āļ›āļīāļ” 11-13 16:00ET
39.38MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš ImageneBio Ord Shs āļšāļĢāļīāļĐāļąāļ—

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

ImageneBio Ord Shs āđ‚āļ›āļĢāđ„āļŸāļĨāđŒ


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™- -
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—- -
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļ- -
āļ‹āļĩāļ­āļĩāđ‚āļ­- -
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™- -
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒ- -
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“- -
āļ—āļĩāđˆāļ­āļĒāļđāđˆ- -
āđ€āļĄāļ·āļ­āļ‡- -
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒ- -
āļ›āļĢāļ°āđ€āļ—āļĻ- -
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ- -
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ- -
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒ- -
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™- -
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļ- -
āļ‹āļĩāļ­āļĩāđ‚āļ­- -

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ ImageneBio Ord Shs


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
493.70K
+51.61%
Ms. Yanina Grant-Huerta
Ms. Yanina Grant-Huerta
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
104.00K
--
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
25.55K
+88.06%
Mr. Joseph P. (Joe) Slattery
Mr. Joseph P. (Joe) Slattery
Independent Director
Independent Director
16.00K
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Yufang Lu, M.D., Ph.D.
Dr. Yufang Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jian (Jonathan) Wang
Dr. Jian (Jonathan) Wang
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Matthew (Matt) Robbins
Mr. Matthew (Matt) Robbins
General Counsel
General Counsel
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
493.70K
+51.61%
Ms. Yanina Grant-Huerta
Ms. Yanina Grant-Huerta
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
104.00K
--
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
25.55K
+88.06%
Mr. Joseph P. (Joe) Slattery
Mr. Joseph P. (Joe) Slattery
Independent Director
Independent Director
16.00K
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia, Ph.D.
Independent Director
Independent Director
--
-100.00%

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ ImageneBio Ord Shs?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ ImageneBio Ord Shs āđ„āļ”āđ‰āđāļāđˆ: Dr. Kristin Yarema, Ph.D.
tradingkey.logo
āļ„āļģāđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡: āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāđāļĨāļ°āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļąāđˆāļ§āđ„āļ›āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļšāļēāļ‡āļ›āļĢāļ°āđ€āļ āļ—āđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ Finsights āđ„āļĄāđˆāđ„āļ”āđ‰āđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđƒāļ” āđ† āđāļĨāļ°āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ”āļąāļ‡āļāļĨāđˆāļēāļ§āđ„āļĄāđˆāļ„āļ§āļĢāļ–āļđāļāļ•āļĩāļ„āļ§āļēāļĄāļ§āđˆāļēāđ€āļ›āđ‡āļ™āļāļēāļĢāđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāđ‚āļ”āļĒ Finsights
āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļ”āđ‰āļēāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļ­āļĒāđˆāļēāļ‡āļĄāļēāļ āļĢāļ§āļĄāļ–āļķāļ‡āļāļēāļĢāļŠāļđāļāđ€āļŠāļĩāļĒāđ€āļ‡āļīāļ™āļ•āđ‰āļ™āļ—āļĩāđˆāļĨāļ‡āļ—āļļāļ™āđ„āļ› āđāļĨāļ°āļ­āļēāļˆāđ„āļĄāđˆāđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļ™ āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ”āļĩāļ•āļ‚āļ­āļ‡āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđ„āļĄāđˆāđ„āļ”āđ‰āļšāđˆāļ‡āļšāļ­āļāļ–āļķāļ‡āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ™āļēāļ„āļ•
Finsights āļ­āļēāļˆāļ­āļ™āļļāļāļēāļ•āđƒāļŦāđ‰āļœāļđāđ‰āļĨāļ‡āđ‚āļ†āļĐāļ“āļēāļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāļšāļļāļ„āļ„āļĨāļ—āļĩāđˆāļŠāļēāļĄāļ§āļēāļ‡āļŦāļĢāļ·āļ­āļŠāđˆāļ‡āđ‚āļ†āļĐāļ“āļēāļšāļ™āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāļŦāļĢāļ·āļ­āļŠāđˆāļ§āļ™āđƒāļ”āļŠāđˆāļ§āļ™āļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­ āđāļĨāļ°āļ­āļēāļˆāđ„āļ”āđ‰āļĢāļąāļšāļ„āđˆāļēāļ•āļ­āļšāđāļ—āļ™āļˆāļēāļāļāļēāļĢāļ—āļĩāđˆāļ„āļļāļ“āļĄāļĩāļ›āļāļīāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ†āļĐāļ“āļē
ÂĐ āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒ: FINSIGHTS MEDIA PTE. LTD. āļŠāļ‡āļ§āļ™āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ—āļļāļāļ›āļĢāļ°āļāļēāļĢ